Case File
efta-02678175DOJ Data Set 11OtherEFTA02678175
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02678175
Pages
3
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
Tazia Smith <->
Sent:
Tuesday, October 29, 2013 11:24 AM
To:
jeffrey epstein
Attachments:
Disclaimer.txt
Classification: Public
Good Morning Jeffrey - As=you likely saw, AAPL recouped immediate losses in the aftermarket yday (tr=ding back up to
—527) after mgmt comments on the conference call suggestin= that lower gross margins were a result of deferrals. Will
watch for any f=llow-through (the sell side has been broadly positive in response to earni=gs) and opportunity to sell
OTM calls today. Fyi only, DB's summary of AAP=.'s earnings report and commentary below (reit 575 tgt).
Tazia
Tazia Smith
Director
Markets Coverage Group
Deutsche Bank Securities, Inc.
Deutsche Asset & Wealth Managem=nt
345 Park Avenue - 26th Floor
New York, NY 10154
Tel: (212) 454=2889
Mobile:
Fax:
E-mail:
From: EVS=EquityFocus
Sent: 10/29/2013 10:01 AM GOT
Su=ject: DB: AAPL.OQ - Chris Whitmore
Classification: Public
Apple Inc (Buy, CP: $529.38, TP: $575.00, AAPL.OQ, Chris Whitmore)
Product cycles kicking into gear
AAPL reported revs of $37.58 and EPS of $8.26 which beat expectation (vs. DB at $36.9B/$8.02; Street at $36.8B/$=.93).
Apple beat on iPhone units (33.8M vs. DB at 32.5M) and iPads (14.1M vs. DB at 12M) and Mac results were light (4.6M
EFTA_R1_01975243
EFTA02678175
vs. DB at 4.8M). iPhone mix and operating leverage translated into OM (26.8% vs. DB at 26.1%) and EPS upside. AAPL will
defer - $900M in the Dec Q related to SW deferrals which impacts cash EPS but not cash flow. Consequently, we trim EPS
est's b=t at —8x CY14 EV/FCF we believe AAPL represents an attractive value; maintain Buy and $575 PT.
Margin guidance was solid after a=justing for software deferrals Apple guided Dec Q revs to $55-58B w=ich beat
expectation (vs. Street at $55.5B). GM's guidance of 36.5-37.5% =ncludes $900M of incremental software deferrals Q/Q
related to including Mavericks, ilife and iWork for free. We estimate - $500M of this total is related to a change in
accounting accrual per device ($5 incremental per iPhone, iPad & iPod touch unit; $20 incremental per Mac). The
remaining -$400M is related to higher volume of unit shipments in the December quarter. When comparing guidance
on a like for like basis (i.e. ex the accounting change) Apple guided 4Q GM's to —38% which was in line with Consensus
on reve=ues of $57B +/- $1.5B which is above Consensus, suggesting improving iPhone 55 supply.
Several catalysts ahead
We expect strong holiday demand for Apple's new product lineup and suspect its guidance will prove conser=ative.
Furthermore, Apple remains very confident in its product pipeline heading into CY14. Specifically, we see multiple
catalysts to support growth over the next 12-18 months including iPhone 6, expansion with China Mobile and further
geographic expansion. In addition, Apple pointed to expanding into new product areas (Apple TV and/or wearables)
which should alleviate innova=ion concerns.
Cutting estimates to reflect acco=nting changes; maintain Buy and $575 PT We adjust CY14 est's to $180B/=$43.90 (vs.
prior to $184B/ $46.00) and introduce CY15 of $188B/ $48.35. Our $575 PT is unchanged and is based on —9x CY14E
EV/FCF; the lower end of its historical 7-29x range. We view the multiple as appropriate given AAPC=;s growth/profit
profile. Risks include product execution, ASP declines & phone / tablet comp'n.
Please click on below link for full report:
http://pu=Ldb-gmresearch.com/p/558-2231/11731481/0900b8c0877292a9.pdf <http://pull.db-gmresearch.com/p/558-
2231/11731481/0900b8c087=292a9.pdf>
Regards,
EVS Equity Focus
Telephone:
- 19
Please ensure all mails are also sent to our shared inbox evs.equityfocus@d=.com to avoid getting overlooked.
This email is sent to you by Evalues=rve on behalf of Deutsche Bank Diese email wurde Ihnen von Evaluese=ve im
Auftrag der Deutschen Bank gesendet
For additional Deutsche Bank research, visit our web site: http=//gm.db.com/equities
Please refer to the disclaimer that applies to the research attached in this email.
This e-mail may contain confidential and/or privileged information. If you are not the intended recipient (or have
received this e-mail in error) please notify the sender immediately and delete this e-mail. Any unauthoriz=d copying,
disclosure or distribution of the material in this e-mail is stric=ly forbidden.
Please refer to http://www.db.com/en/content/eu_disclosures.htm for additional EU corporate and regulatory
disclosures.
2
EFTA_R1_01975244
EFTA02678176
This communication may contain confid=ntial and/or privileged information.
If you are not the intended recipient (or have received this communication<=r> in error) please notify the sender
immediately and destroy this
communication. Any unauthorized copying, disclosure or distribution of thear> material in this communication is
strictly forbidden.
Deutsche Bank does not render legal or tax advice, and the information
contained in this communication should not be regarded as such.
3
EFTA_R1_01975245
EFTA02678177
Technical Artifacts (10)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
gm.db.comDomain
ldb-gmresearch.comDomain
streetaccount.comPhone
2678175Phone
2678176Phone
2678177Phone
558-2231URL
http://pu=Ldb-gmresearch.com/p/558-2231/11731481/0900b8c0877292a9.pdfURL
http://pull.db-gmresearch.com/p/558URL
http://www.db.com/en/content/eu_disclosures.htmRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.